October 9, 2026European Journal of Heart Failure
GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF.
Key result
Full-dose GDMT linked to ~20 mg greater loop diuretic reduction at 90 days in HF.
- P<0.001
- n=1,075
Why the study?
It was unknown whether optimizing guideline-directed medical therapy reduces loop diuretic requirements and how diuretic dose relates to heart failure severity, outcomes, and treatment benefit.
Does achieving 100% target doses of GDMT reduce loop diuretic requirements in heart failure patients?
Key Points
- To assess whether rapid up-titration of guideline-directed medical therapy reduces loop diuretic requirements and whether baseline diuretic dose alters the clinical benefit of high-intensity care in heart failure.
- Post-hoc analysis of the randomized STRONG-HF trial assessing 1,075 patients with available post-randomization loop diuretic data.
- Patients were categorized by baseline furosemide-equivalent dose, and changes in daily dose at day 90 were evaluated according to the achievement of 100% target doses of guideline-directed medical therapies (RAS inhibitors, beta-blockers, and MRAs).
- Achieving 100% of target doses across all three drug classes significantly lowered day 90 furosemide-equivalent requirements by -21.94 (SD 52.46) mg versus -1.55 (SD 49.886) mg in patients not reaching targets (p<0.001), driven primarily by beta-blockers (-18.42 [SD 49.61] mg, p<0.001).
- Baseline loop diuretic dose category was not independently associated with 180-day all-cause death or heart failure rehospitalization, but doubling the diuretic dose was associated with higher all-cause mortality (adjusted HR 1.47, 95% CI 1.04-2.09).
Study Design
Type
Observational (n=1,075)
Structured PICO
Does achieving 100% target doses of GDMT reduce loop diuretic requirements in heart failure patients?
P
Population
1,075 heart failure patients with post-randomization loop diuretic data from the STRONG-HF trial.
E
Exposure
Achieving 100% of target doses of all guideline-directed medical therapy (GDMT) classes (RASi, beta-blocker, MRA)
C
Comparator
Not reaching 100% of target doses of GDMT
O
Outcome
Change in furosemide-equivalent loop diuretic dose at day 90, and composite of all-cause death or HF rehospitalization at 180 dayscomposite
Main Result
Absolute Event Rate: -21.94% vs -1.55%
p-value: p=<0.001
Optimizing guideline-directed medical therapy to target doses significantly reduces loop diuretic requirements in patients with heart failure.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“When the patient has no overt fluid overload but still some residual congestion, probably it's much better to uptitrate GDMT than to keep on pushing on diuretics because diuretics do not change the trajectory of the disease—neurohormonal blockade does.”
SGStephen GreeneCardiologist, Duke Clinical Research Institute
“STRONG-HF was a conservative estimate on what we're going to get if we use comprehensive, disease-modifying, quadruple medical therapy.”
LALarry AllenHeart failure specialist, University of Colorado
“It helps me feel reassured about being relatively aggressive about rapid intensification of guideline-directed medical therapies starting in the hospital.”
Implication
Optimizing GDMT to target doses may lower diuretic needs in HF; leaves open independent effects on outcomes.
Abstract
AIMS: Loop diuretics (LD) are the cornerstone of congestion management in heart failure (HF), but whether their requirement can be reduced by optimizing disease-modifying therapy is unknown. METHODS: In this post-hoc analysis of STRONG-HF (n=1,075 with post-randomization LD data), we assessed whether up-titration of guideline-directed medical therapy (GDMT) lowers LD demand, and whether LD dose reflects HF severity, predicts outcome, or modifies the benefit of high-intensity care. Patients were grouped by furosemide-equivalent dose; change at day 90 was compared by achievement of 100% target GDMT doses. RESULTS: Higher LD doses marked more severe HF. Achieving 100% of target doses of all GDMT classes (RASi, beta-blocker, MRA) translated into a substantially lower diuretic requirement: furosemide-equivalent dose at day 90 fell by -21.94 (SD 52.46) mg versus -1.55 (SD 49.886) mg in those not reaching targets (p<0.001); beta-blockers showed the largest effect of any single class -18.42 (SD 49.61) mg, (p<0.001). LD dose category was not independently associated with the primary endpoint (all-cause death or HF rehospitalization at 180 days) or its components; only LD dose doubling was associated with higher all-cause mortality (adjusted HR 1.47, 95% CI 1.04-2.09), without association with the primary endpoint or rehospitalization (both p>0.05). The benefit of high-intensity care was consistent across LD dose groups (no treatment-by-dose interaction). CONCLUSIONS: GDMT optimization acted as diuretic-sparing therapy: reaching target doses, particularly of all three classes, was associated with markedly lower LD requirement. LD dose mirrored HF severity but neither consistently predicted outcome nor modified the benefit of up-titration.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Biegus et al. (2026) conducted an observational in Heart failure (n=1,075). Achieving 100% of target doses of all GDMT classes vs. Not reaching targets was evaluated on Change in furosemide-equivalent dose at day 90 (p=<0.001).